Iron(III) complex enables a controlled and slow release of bioavailable iron to iron-binding proteins with little risk of free iron. Evidence of a therapeutic response can be seen within a few days of administration of iron(III) as an increase in the reticulocyte count.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B03AC | Iron trivalent, parenteral preparations | B Blood and blood forming organs → B03 Antianemic preparations → B03A Iron preparations |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| MONOFER Solution for injection / infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
Iron (III) isomaltoside is an active ingredient of these brands:
Australia (AU)Austria (AT)Brazil (BR)Croatia (HR)Estonia (EE)Finland (FI)Hong Kong (HK)Lithuania (LT)Netherlands (NL)New Zealand (NZ)Romania (RO)Singapore (SG)South Africa (ZA)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
